Key points are not available for this paper at this time.
< 0.001). Higher market entry treatment cost for newly approved drugs were associated with biologics, orphan status, US sponsor companies, chronic use, therapeutic intent, and indications for oncology or genetic disorders.
Althobaiti et al. (Mon,) studied this question.